glp 1 agonists moa Non-insulin injectable antidiabetic drugs - GLP-1 and amylinomimetics Mechanisms of Action and Therapeutic

Consequently, several therapeutic approaches have aimed to antagonize GCG activity in the management of T2DM

doi: 10.2337/db11-0489

While these unregulated sources may promise quick results, they often come with serious health risks, especially for individuals with existing mental health conditions or a history of eating disorders

In 2023 a survey undertaken among 300 patients by Morgan Stanley revealed that the reduction in calorie intake per patient of between 20 and 30 percent could have 'long term implications for food-related businesses, particularly those selling unhealthier foods such as high-fat, sweet and salty products' (Economist)

No Generic Available: Eli Lilly holds patents on tirzepatide until around 2036-2040, meaning no true generic versions will be available for years